3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
24
NIH
10
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Myeloid, Acute
5
Glioblastoma
4
Breast Neoplasms
4
Melanoma
3
Pathologic Complete Response
2
Ovarian Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumor
1
Smoldering Multiple Myeloma
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoma, Follicular
1
Glioma
1
Breast Neoplasms, Male
1
Brain Neoplasms
1
Advanced Ovarian Cancer
1
Advanced Cancer
1
Interventions
Rituximab
91
Cyclophosphamide
31
Lenalidomide
28
Bendamustine Hydrochloride
25
Prednisone
21
Vincristine
20
obinutuzumab
17
Doxorubicin
17
fludarabine
14
ibrutinib
13
tazemetostat
9
idelalisib
9
Prednisolone
9
Deoxycholic Acid
9
parsaclisib
8
zanubrutinib
7
venetoclax
7
tofacitinib
7
tisagenlecleucel
5
pembrolizumab
5
ofatumumab
5
ibritumomab tiuxetan
5
duvelisib
5
Gemcitabine
5
Bortezomib
5
durvalumab
4
aflibercept
4
R-CHOP protocol
4
Methylprednisolone
4
Methotrexate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, Follicular
×
sargramostim
×
Clear all
NCT00308087
2013-12-27
PREMIER
Sanofi
Phase 2
Terminated
75 enrolled
12 charts